Market Data 
Markets
Replies to post #40689 on SiNtx Technologies Inc (SINT)
Certain of our outstanding shares of convertible preferred stock and warrants contain full-ratchet anti-dilution protection, which may cause significant dilution to our stockholders.
We currently have outstanding 26 shares of Series B convertible preferred stock convertible into an aggregate of 114,400 shares of Common Stock, and warrants issued in October 2022 that are exercisable for an aggregate of 616,641 shares of Common Stock. The Series B convertible preferred stock and October 2022 warrants contain full-ratchet anti-dilution provisions which, subject to limited exceptions, would reduce the conversion price of the Series B preferred stock (and increase the number of shares issuable under the Series B preferred stock) and reduce the exercise price of the October 2022 warrants in the event that we in the future issue Common Stock, or securities convertible into or exercisable to purchase Common Stock, at a price per share lower than the conversion price or exercise price then in effect. Depending upon how such provisions are interpreted, the alternative cashless exercise provision contained in the Class C Warrants and Class D Warrants could potentially result in a significant reduction in the conversion or exercise price of the Series B convertible preferred stock and October 2022 warrants. Our outstanding 26 shares of Series B preferred stock are, prior to this offering, convertible into 114,400 shares of Common Stock at a conversion price of $0.25 per share. The October 2022 warrants are exercisable at an exercise price of $0.25 per share. These full ratchet anti-dilution provisions will likely be triggered by the issuance of the Units in this offering.
Investors participating in the February 2010 closing that purchased at least 12,500 shares of our Series E convertible preferred stock had the right to convert, on a one-for-one basis, shares of our previously issued Series A convertible preferred stock, Series B convertible preferred stock, Series C convertible preferred stock and Series D convertible preferred stock already owned by the investor into a corresponding new series of our convertible preferred stock with a more favorable conversion rate. Directors, officers and beneficial owners of more than 5% of our common stock, on an as converted basis, and their affiliates participated in this conversion right as follows:
SEVERE GEOMAGNETIC STORM--THE STRONGEST IN YEARS: As predicted, a CME struck Earth's magnetic field on March 24th (1437 UT). The impact opened a crack in our planet's magnetosphere and sparked a severe G4-class geomagnetic storm--the strongest geomagnetic storm since Sept. 2017.
examples of their medical applications that relate to spinal, orthopedic and dental implants, bone grafts and scaffolds, platforms for intelligent synthetic neural circuits, antibacterial and antiviral particles and coatings, optical biosensors, and nano-photonic waveguides for sophisticated medical diagnostic devices are all covered in the research reviewed herein. The examples provided convincingly show that silicon nitride is destined to become a leader to replace titanium and other entrenched biomaterials in many fields of medicine.
Silicon nitride, silicon carbide and diamond-like carbon as non-oxide ceramics are considered to be the new generation of materials used in hip prosthetics, particularly in the manufacture of acetabular cups, due to their excellent biocompatibility, osteointegration, and tribological and mechanical properties, but all three materials need more study. However, silicon nitride is the nearest to commercialization, through businesses such as Amedica Corp. and SyntX Technologies
AI
